Analysis
Forus, an AI health company formerly known as Tandem, raised a new round according to Bloomberg:
- Series C — $150 million, led by Bain Capital Ventures.
- New valuation — $3 billion, roughly triple its prior mark.
- Total raised — more than $300 million, with existing investors Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures and SV Angel all joining the round.
Founded in New York in 2023 by Sahir Jaggi, Forus deploys AI agents inside the prescribing workflow: when a doctor writes a prescription, the software checks medication history, verifies payer coverage, files prior-authorization paperwork, handles appeals after insurance denials, and routes the order to a pharmacy without staff intervention. The company rebranded from Tandem earlier in its life as the product shifted from a narrower point tool into the full prescribing-to-pharmacy pipeline it sells today. Forus says its network now reaches providers in 85% of U.S. residential ZIP codes across all 50 states, offered free to providers and patients -- a distribution strategy that trades near-term revenue for the fastest possible path to the kind of national coverage that makes the product genuinely useful to a prescriber on day one.
“- Series C — $150 million, led by Bain Capital Ventures.”
That free-to-provider model means Forus's revenue sits entirely on the other side of the transaction, with payers and pharmaceutical manufacturers who benefit when prior-authorization friction gets resolved faster or when a prescription reaches a pharmacy without falling through administrative cracks. Prior authorization is one of the most-cited sources of physician burnout and delayed care in U.S. healthcare, and automating the paperwork around it is a crowded, well-funded category:
- CoverMyMeds -- founded 2008, acquired by McKesson in 2017 for roughly $1.2 billion, and still the incumbent most providers already have installed in their workflow.
- Cohere Health -- founded 2019, focused on health-plan-side automation rather than the point-of-prescribing workflow Forus targets.
- Rhyme -- an Ohio-based prior-authorization specialist founded in 2016, competing more narrowly on the payer-approval step alone.
At $3 billion for a company still built on a free product, Forus's valuation is a bet that reach converts into payer and pharma revenue faster than competitors with a narrower but already-monetized footprint can catch up.
